Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Collegium Pharmaceutical and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Collegium Pharmaceutical and Alpha Cognition, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Collegium Pharmaceutical | 1 | 1 | 7 | 1 | 2.80 |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
Collegium Pharmaceutical presently has a consensus price target of $44.88, suggesting a potential upside of 85.36%. Alpha Cognition has a consensus price target of $18.00, suggesting a potential upside of 117.13%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than Collegium Pharmaceutical.
Volatility and Risk
Collegium Pharmaceutical has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500.
Valuation and Earnings
This table compares Collegium Pharmaceutical and Alpha Cognition”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Collegium Pharmaceutical | $780.57 million | 1.01 | $62.87 million | $1.00 | 24.21 |
| Alpha Cognition | $10.22 million | 17.67 | -$20.67 million | ($1.10) | -7.54 |
Collegium Pharmaceutical has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Collegium Pharmaceutical beats Alpha Cognition on 8 of the 12 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
